Trade DiaMedica Therapeutics Inc. - DMAC CFD

DiaMedica Therapeutics Inc. Company profile

About DiaMedica Therapeutics Inc

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for neurological and kidney diseases, such as acute ischemic stroke (AIS) and chronic kidney disease (CKD). The Company's lead product DM199 mimics the behavior of naturally occurring human KLK1 proteins to preserve and restore circulation to stroke-damaged tissue and improve overall kidney function. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. DM199 therapy has the potential to improve circulation and overall function of critical systems, as well as reduce inflammation and oxidative stress. The Company also has other product pipelines for IgA Nephropathy and African Americans with CKD.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, DiaMedica Therapeutics Inc revenues was not reported. Net loss increased 11% to $13.6M. Higher net loss reflects General and administrative - Balancing increase of 23% to $3.8M (expense), Research and development - Balancing increase of 7% to $8.3M (expense), Governmental assistance research incen decrease from $205K (income) to $0K.